Vermilion Energy (VET) Receives a Hold from RBC Capital
RBC Capital analyst Gregory Pardy maintained a Hold rating on Vermilion Energy (VET – Research Report) yesterday and set a price target of C$14.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pardy covers the Energy sector, focusing on stocks such as Canadian Natural, Imperial Oil, and Vermilion Energy. According to TipRanks, Pardy has an average return of 18.3% and a 58.50% success rate on recommended stocks.
In addition to RBC Capital, Vermilion Energy also received a Hold from BMO Capital's Jeremy Mccrea in a report issued on May 23. However, on May 20, J.P. Morgan maintained a Sell rating on Vermilion Energy (NYSE: VET).
VET market cap is currently $1.03B and has a P/E ratio of -42.58.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Why BioNTech Stock Soared Today
BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments to BioNTech could exceed $11 billion over time. 10 stocks we like better than BioNTech Se › BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID. The German biotech announced this morning it is partnering with pharmaceuticals giant Bristol Myers Squibb (NYSE: BMY) to "co-develop and co-commercialize" BioNTech's drug candidate BNT327 as an immunotherapy against multiple kinds of cancer. BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is already involved in "multiple" ongoing clinical trials, including an advanced phase 3 trial testing its usefulness in treating breast cancer and both small cell and non-small cell lung cancer. BioNTech CEO Dr. Uğur Şahin expressed the belief that "BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications." Bristol CEO Christopher Boerner agreed that BNT327 has "significant potential for transforming the standard of care for patients with solid tumors." There are more immediate benefits for BioNTech stock, beginning with Bristol Myers Squibb paying BioNTech $1.5 billion up front for the rights to team up and a further $2 billion in noncontingent payments through 2028 as drug development continues. Additional developmental, regulatory, and commercial milestones, which are contingent on successful development, could add a further $7.6 billion to BioNTech's balance sheet over time. With its lucrative COVID days behind it, BioNTech reported nearly $690 million in losses last year and turned free-cash-flow negative. A tidal wave of cash from Bristol Myers Squibb could really come in handy right about now. Before you buy stock in BioNTech Se, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BioNTech Se wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Why BioNTech Stock Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why IonQ Stock Soared 47% in May
IonQ shares soared last month as the CEO compared it to Nvidia. The company also got a boost from its first-quarter earnings report and its acquisition of Lightsynq. Trading at a lofty price-to-sales ratio of over 100, the stock could easily fall from here. 10 stocks we like better than IonQ › Shares of IonQ (NYSE: IONQ), a developer of quantum computers and related platforms, were soaring last month, primarily in response to favorable coverage in Barron's, and an article that said it was aiming to be "the Nvidia of quantum computing." Additionally, the company reported first-quarter earnings that were generally in line with estimates and benefited from a broader risk-on sentiment in the market as worries about a trade war and a weakening economy faded. According to data from S&P Global Market Intelligence, the stock finished the month up 47%. As you can see from the chart, shares surged on the Barron's report on May 22, but then gave up some of those gains the following week as bullishness in the stock seemed to fade following an Nvidia's earnings report that did not highlight quantum computing. Quantum stocks generally rallied last month, as some investors bet that it could be the next big technology after artificial intelligence (AI), but IonQ, which is the most valuable of the group of quantum stocks, got a particular boost on May 22 thanks to the coverage in Barron's, as IonQ soared 37% that day. In an interview with Barron's, CEO Niccolo de Masi said, "We're in the business of quantum just like Nvidia and Broadcom are in the business of classical GPUs," adding, "I believe IonQ will be the Nvidia player. There will be other people that copy us and follow us; they have always copied and followed us." It was a bold statement coming from a company that earlier in May reported just $7.6 million in revenue in its first quarter, or less than 0.1% of what Nvidia and Broadcom reported. IonQ also continues to lose money as it invests in its technology. In the first quarter, the company reported a generally accepted accounting principles (GAAP) net loss of $32.3 million, and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $35.8 million. Last month, the company also signed a memorandum of understanding (MOU) with Korea Institute of Science and Technology (KISTI), a technology research institute and supercomputing center. According to the MOU, the two companies will work together to collaborate in multiple areas to advance quantum computing. IonQ is now targeting revenue of $75 million-$95 million for the full year following its acquisition of Lightsynq, though justifying a market cap of $10 billion at that level of revenue seems difficult, especially when the company reported flat growth in the first quarter. Investors bullish on quantum computing might consider taking a small position in the stock, but it could easily plunge, considering it's been bid up on mostly hype. Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Jeremy Bowman has positions in Broadcom and Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Why IonQ Stock Soared 47% in May was originally published by The Motley Fool Sign in to access your portfolio
Business Insider
an hour ago
- Business Insider
CFRA upgrades Dollar General (DG) to a Hold
In a report released today, Arun Sundaram from CFRA upgraded Dollar General (DG – Research Report) to a Hold, with a price target of $118.00. The company's shares closed today at $112.57. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Sundaram is a 3-star analyst with an average return of 8.0% and a 63.16% success rate. Dollar General has an analyst consensus of Moderate Buy, with a price target consensus of $97.20, representing a -13.65% downside. In a report released today, Telsey Advisory also initiated coverage with a Hold rating on the stock with a $100.00 price target. Based on Dollar General's latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $10.3 billion and a net profit of $191.22 million. In comparison, last year the company earned a revenue of $9.86 billion and had a net profit of $401.81 million Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DG in relation to earlier this year. Most recently, in April 2025, EMILY C TAYLOR, the EVP & Chief Merchandising Ofc of DG sold 809.00 shares for a total of $76,620.39.
